Anupam Rama
#12 out of 1697 analysts
JP Morgan
Automatically Tracked
Analyst ratings are aggregated from multiple third-party sources and may be inaccurate, incomplete, or outdated. All ratings remain the sole responsibility of their original providers. Rankings are based on the 3-year performance of a simulated $100,000 account trading on analyst ratings data.
Gain and growth charts are calculated per selected timeframe:
277.82%
Gain +32.4%
Monthly
1.15%
Yearly
14.73%
Drawdown
82.81%
$1.37M
Equity
Holdings
$1.2M
Cash
$169,431.29
Investment
$632,853.84
$948,691.09
Profit +$334,514.12
Realized
$383,926.21
Unrealized
$564,764.88
Dividends
$0
$169,431.29
Cash
Deposits
$418,358.92
Withdrawals
$0
Commissions
$0
Goals
Avg. 0% completed goals
Today
Compared To Yesterday
Gain
32.4%
Profit
$334,514.12
Win %
51%
This Week
Compared To Last Week
Gain
32.45%
Profit
$334,514.12
Win %
51%
This Month
Compared to last month
Gain
14.81%
Profit
$176,157.7
Win %
53%
This Year
Compared to last year
Gain
28.3%
Profit
$301,202.57
Win %
62%
KOD Kodiak Sciences Inc.
+171.72%
+$330,131.8 
ANNX Annexon, Inc.
+5.36%
+$1,350.78 
REPL Replimune Group Inc.
+2.91%
+$2,056.98 
BBIO BridgeBio Pharma, Inc.
+2.52%
+$2,185.64 
CTMX CytomX Therapeutics Inc.
+0.74%
+$455.66 
KLRS Kalaris Therapeutics, Inc.
+0.69%
+$18.34 
KARD Kardigan, Inc.
+0.51%
+$164.01 
VERA Vera Therapeutics Inc.
+0.46%
+$172.78 
KNSA Kiniksa Pharmaceuticals International, plc
+0.19%
+$244.93 
ALVR Kalaris Therapeutics, Inc.
0%
$0 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 1987 | Longs Won 980/1842 53% | Profit Factor 3.05 |
| Profitability | Shorts Won 81/145 55% | Standard Deviation $8,518.05 |
| Average Win $1,330.62 | Best Trade (Sep 28) $341,411.43 | Sharpe Ratio -188.54 |
| Average Loss -$500.11 | Worst Trade (Apr 14) -$44,145.88 | Z-Score -14.76 (100%) |
| Commissions $0 | Avg. Trade Length 4m 2w | Expectancy $477.45 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.01% | 0.17% | 1.83% | 15.13% |
| Consecutive Losing Trades | 2,732 | 2,459 | 2,186 | 1,913 | 1,639 | 1,366 | 1,093 | 820 | 546 | 273 |
Hover over the desired column for a detailed explanation.
Returns
Overall, Monthly| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
| ALVR Kalaris Therapeutics, Inc. | -501.9 | $2,143.12 | $1,565.94 | - | $577.18 | 26.93% | 0.0 |
| ANNX Annexon, Inc. | 6,927.07 | $26,815.77 | $26,565.31 | - | -$250.46 | -0.93% | +5.357% |
| BBIO BridgeBio Pharma, Inc. | 1,324.63 | $73,226.03 | $89,041.84 | - | $15,815.81 | 21.6% | +2.516% |
 CELC Celcuity Inc. | 1,613.02 | $41,408.83 | $127,227.21 | - | $85,818.38 | 207.25% | -0.811% |
| CTMX CytomX Therapeutics Inc. | 22,783.07 | $66,330.35 | $61,969.94 | - | -$4,360.41 | -6.57% | +0.741% |
| KARD Kardigan, Inc. | 2,186.85 | $32,243.27 | $32,507.54 | - | $264.27 | 0.82% | +0.507% |
| KLRS Kalaris Therapeutics, Inc. | 917.15 | $16,103.24 | $2,696.41 | - | -$13,406.83 | -83.26% | +0.685% |
| KNSA Kiniksa Pharmaceuticals International, plc | 1,749.53 | $82,120.77 | $131,599.99 | - | $49,479.22 | 60.25% | +0.186% |
| KOD Kodiak Sciences Inc. | 5,942.97 | $85,877.87 | $522,386.77 | - | $436,508.9 | 508.29% | +171.716% |
 OLMA Olema Pharmaceuticals Inc. | 4,387.55 | $48,092.73 | $37,952.32 | - | -$10,140.41 | -21.09% | -1.143% |
 RARE Ultragenyx Pharmaceutical Inc. | 1,063.76 | $16,610.66 | $15,158.62 | - | -$1,452.04 | -8.74% | -1.724% |
| REPL Replimune Group Inc. | 5,713.84 | $63,573 | $72,680.01 | - | $9,107.01 | 14.33% | +2.913% |
 SNDX Syndax Pharmaceuticals Inc. | 2,086.85 | $39,467.06 | $37,459 | - | -$2,008.06 | -5.09% | -1.374% |
| VERA Vera Therapeutics Inc. | 1,151.83 | $38,841.14 | $37,653.46 | - | -$1,187.68 | -3.06% | +0.461% |
No Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
